Prostate caner
Conditions
Interventions
Healthy Control Group:None
Benign Prostate Hyperplasia Patient Group:None
Prostate Cancer Patient Group:None
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Prostate cancer patient group: 1. Age: 18-80 years old; Gender: Male; 2. Clinical diagnosis: confirmed prostate cancer by pathological examination or imaging examination; 3. Disease stage: patients with prostate cancer at different stages, including localized, locally advanced and metastatic prostate cancer; 4. Complete clinical information. Group of patients with benign prostatic hyperplasia: 1. Age: 18-80 years old; Gender: Male; 2. Clinical diagnosis: clinical symptoms, physical examination and imaging examinations (such as ultrasound) confirm the diagnosis of prostatic hyperplasia; 3. Complete clinical information. Health Examination Group: 1. Age: 18-80 years old; Gender: Male; 2. T-PSA (total prostate-specific antigen) in the range of 0-4 ng/ml; 3. In good health in the past, no history of prostate disease or other serious chronic diseases; 4. Complete clinical information.
Exclusion criteria
Exclusion criteria: 1. Other serious diseases: patients with severe cardiovascular diseases, liver and kidney insufficiency, etc., which affect the results of the study, are excluded. 2. Participation in other clinical trials: Patients who are participating in other clinical trials that may interfere with this study are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The diagnostic efficacy of the novel biomarker TREM2 and AR in combination for prostate cancer; | — |
Secondary
| Measure | Time frame |
|---|---|
| The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the combined application of novel biomarkers TREM2 and AR in the diagnosis of prostate cancer;The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of PSA testing in the diagnosis of prostate cancer;differential expression levels of novel biomarkers TREM2 and AR in different stages of prostate cancer;The correlation coefficient of the combined application of novel biomarkers TREM2 and AR for prostate cancer staging; | — |
Countries
China
Contacts
Public ContactGuanmin Jiang
Fifth Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed